CuraVac is an innovative young company founded to take a newly discovered technique for creating therapeutic vaccines against autoimmune diseases from discovery through to being available for the treatment of humans.
Typical autoimmune diseases that should be treatable by CuraVac vaccines include myasthenia gravis, multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosis.
The pioneering vaccine, already in development, is for the treatment of myasthenia gravis.
Through this web site, CuraVac aims to bring its activities to the attention of the wider public who want to know about CuraVac and its team and to offer an investment or donation opportunity to those who wish to support its work.
In 2009, the myasthenia gravis therapeutic vaccine, the first vaccine in a series, was granted Orphan Drug Designation in Europe by a team of 27 independent experts of the 27 European member states.
In 2011, the MG therapeutic vaccine was granted Orphan Drug Designation in the USA.by the FDA
In 2013, CuraVac created a European consortium of four companies and one University Medcal Center that receives the support of the FP7 2013 Health Inovation to conduct clinical trials of the MG therapeutic vaccine: MYASTERIX.
The first in human trial of the MG therapeutic vaccine will begin in Europe during the first half of 2015.
CuraVac is supported by The Myasthenia Gravis Garden State Chapter.
Wall street Journal, September 2, 2010 :
RTL TV Night News Program, September 6, 2010: